

EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001 Tel: 022-35661373 / 35664530 Email: <u>enquiries@ebnl.org</u> Website: <u>www.ebnl.org</u> Investors Grievance Email: <u>investors@ebnl.org</u> CIN No. L24110MH1992PLC065942

EBN/2024/S-040

February 06, 2024

The Manager The Department of Corporate Service BSE Limited Floor 25, Phiroze Jeejebhoy Towers Dalal Street, Fort, Mumbai – 400 001

Dear Sir / Madam,

Sub: Disclosure pursuant to Regulation 30 & Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code No. 524768

In furtherance to our letter dated February 03, 2024, intimating the outcome of the Board Meeting, please find enclosed the newspaper cutting, wherein the Un-Audited Financial Results of the Company for the Third quarter ended December 31, 2023, was published in Free Press Journal and Nav Shakti on February 06, 2024.

The aforesaid information will also be hosted on the Company's website i.e., www.ebnl.org.

You are kindly requested to take this on record.

Thanking you,

Yours faithfully, For Emmessar Biotech & Nutrition Limited



Priyanka O. Sharma Company Secretary & Compliance Officer ICSI M. No. A52518 Encl: As above

Emmessar Biotech & Nutrition Ltd. Registered Office: Plot No. T-3/2, MIDC, Taloja, Raigad Dist., Maharashtra - 410 208. CIN: L24110MH1992PLC06594229 ebnl

T	Particulars		1 months	Unaudited	mit un h		Audited
Sr.		Quarter Ended			Nine months Ended		Year Ended
No.		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Revenue from Operations	32.79	8.43	42.73	47.99	70.28	101.92
I	Other Income	52.50	52.73	44.48	150,79	131.79	175.07
11	Total Income (I + II)	85.29	61.16	87.21	198.78	202.07	276.99
V	Expenses		Continue au	a de la competition de la comp	1223		
-	Cost of material consumed	0.89	1.35	2.13	3.86	11.82	6.88
	Purchase of Stock-trade	10.88	-	18.98	10.88	18.98	37.66
-	Change in Inventories of Finished goods	2.19	0.98	(5.00)	3.14	(4.42)	-4.56
	Employee Benefit Expenses	29.04	21.49	25.39	72.79	63.82	83.71
	Depreciation & Amortisation of Assets	2.44	2.44	2,37	7.32	6.98	9.36
-	Other Expenditure	10.40	6.16	18.37	26.65	32,91	47.25
	Total Expenses (IV)	55.84	32.42	62.24	124.64	130.09	180.30
V	Profit / (loss) from Operations before tax (III - IV)	29.45	28.74	- 24.97	74.14	71.98	96.69
VI	Exceptional Items		-		-		
VII	Profit / (loss) before Tax	29.45	28.74	24.97	74.14	71.98	96.69
VIII	Tax Expense		-				
VILL	1. Current Tax	(9.00)	(8.05)	(10.00)	(21.55)	(20.00)	-14.91
2	2. Deferred Tax	(7.56)	(0.96)	(17.17)	(14.48)	(21.17)	-21.18
-	3. MAT Credit	(,,)	No. and	1 1 1 1 1		- Incode	-13.77
-	4. Excess / (short) provision of earlier years	-				dinn.	3.55
IX	Net Profit / (loss) after tax (V - VI)	12.89	19.73	(2.20)	38.11	30.81	50.38
X	Other Comprehensive Income				-		(0.82)
XI	Total comprehensive income		1	a alter	177 mill		
~	and Other Comprehensive Income	12.89	19.73	(2.20)	38.11	30.81	49.56
XII	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61	499.61
All	(Face Value of the share)	10.00	10.00	10.00	10.00	10.00	10.00
-	Earning per Shares		0.0	C. Starting	DAUNES		
-	Basic	0.26	0.39	(0.04)	0.76	0.62	0.99
-	Diluted	0.26	0.39	(0.04)	0.76	0.62	0.99

Notes:

The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 3rd February 2024 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.

The Company operates two segments is. Healthcare and Rent on Leasehold Land.
No Investors Complaint received during the quarter ended 31st December 2023

Segmentwise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st Dec 2023

(7 in lakhs)

				and the second second			(t in Jakna
Sr. No.	Particulars	Unaudited					Audited
		Quarter Ended			Nine Months ended		Year Ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
1	Segment Revenue	- 100 GES 1	L'Silver	A WOOD	1. June		
a	Healthcare	32.79	8.43	42.73	47.99	70.28	101.92
	Rent on leasehold land	37.16	37,16	37.16	111.48	111.48	148.64
c	Others	15.34	15.57	7.32	39.30	20.31	26.43
	Total:	85.29	61.16	87.21	198.78	202.07	276.99
	Less: Inter Segment Revenue			5	1	-	-
	Net Sales / Income from Operations	85.29	61.16	87.21	198.78	202.07	276.99
2	Segment Results (Profit / Loss) before tax	-	100 M	ALC: NOT	CONTRACTOR OF		
a	Healthcare	18.27	5.38	25,10	27.97	41.62	58.61
b	Rent on leasehold land	36.93	36.93	36.93	110.79	110.79	148.64
c	Others	15.34	15.57	7.32	39.30	20.31	26.43
	Total:	70.55	57.88	69.35	178.06	172.72	233.68
	Less:	1 Land			a Phanett	0	The second second
	Interest		1.		2.19	· · ·	
	Other Unallocable Expenditure (net off)	41.10	29.14	44.38	103.92	100.74	136.99
	Total Profit before Tax	29.45	28.74	24.97	74.14	71.98	96.69
3	Capital Employed		1		In the second second		
10) 	(Segment Assets - Segment Liabilities)		12.2		- milder	A State	
a	Healthcare	23.04	11.47	10.22	23.04	10.22	1000
b	Rent on leasehold land	(1.41)	(1.18)	(1.41)	(1,41)	(1.41)	
c	Others	713.46	505.31	628.52	713.46	628.52	646.42
-	Total:	735.09	515.60	637.33	735.09	637.33	659.32

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature. The above results were taken on record at a meeting of the Board of Directors held on 3rd February, 2024.

Mumbai 3rd February 2024		Chairman & Managing Director DIN: 00090266
	Srinivasa Ragi	r Biotech & Nutrition Limited havan Mathurakavi Ayyangar

FREE PRESS JOURNAL www.freepressjournal.in MUMBAI | TUESDAY | FEBRUARY 6, 2024

	UNAUDITED FINANCIAL F	IESULTS	AS ON 3	SIST DEC	EMBER	2023	(₹ in lakh
-			11.040	Unaudited	Geo all		Audited
Sr.	Particulars	Q	ths Ended	Year Ende			
No.		31.12.2023	30.09.2023	31.12.2022	31.12.2023 31.12.2022		31.03.202
-	Revenue from Operations	32.79	8.43	42.73	47.99	70.28	101.92
1	Other Income	52.50	52.73	44.48	150.79	131.79	175.07
11	Total Income (I + II)	85.29	61.16	87.21	198.78	202.07	276.99
IV	Expenses						
IV	Cost of material consumed	0.89	1.35	2.13	3.86	11.82	6.88
	Purchase of Stock-trade	10.88		18.98	10.88	18.98	37.66
-	Change in Inventories of Finished goods	2,19	0.98	(5.00)	3.14	(4.42)	-4.5
-	Employee Benefit Expenses	29.04	21.49	25.39	72.79	63.82	83.7
	Depreciation & Amortisation of Assets	2.44	2.44	2.37	7.32	6.98	9.36
-	Other Expenditure	10.40	6.16	18.37	26.65	32.91	47.25
-	Total Expenses (IV)	55.84	32.42	62.24	124.64	130.09	180.3
V	Profit / (loss) from Operations before tax (III - IV)		28.74	24.97	74.14	71.98	96.6
VI	Exceptional Items	-					1
VI	Profit / (loss) before Tax	29.45	28.74	24.97	74.14	71.98	96,6
	Tax Expense	-			1		
VIII	1. Current Tax	(9.00)	(8.05)	(10.00)	(21.55)	(20.00)	-14.9
-	2. Deferred Tax	(7.56)	(0.96)	(17.17)	(14.48)	(21.17)	-21.1
-	3. MAT Credit			1			-13.7
	4. Excess / (short) provision of earlier years						3.5
IX	Net Profit / (loss) after tax (V - VI)	12.89	19.73	(2.20)	38.11	30.81	50.3
X	Other Comprehensive Income	TTANK -			10		(0.8
XI	Total comprehensive income	-		1		- and	-
	and Other Comprehensive Income	12.89	19.73	(2.20)	38.11	30.81	49.5
XII		499.61	499.61	499.61	499.61	499.61	499.6
1	(Face Value of the share)	10.00	10.00	10.00	10.00	10.00	10.0
-	Earning per Shares		THE L			1 annual	
-	Basic	0.26	0.39	(0.04)	0.76		
-	Diluted	0.26	0.39	(0.04)	0.76	0.62	0.9

The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 3rd February 2024 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
The Company operates two segments is. Healthcare and Rent on Leasehold Land.

3. No investors Complaint received during the quarter ended 31st December 2023

Segmentwise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st Dec 2023

for the quarter and mile months chock of st nee were							
	Particulars	Unaudited					Audited
Sr.		Quarter Ended			Nine Months ended		Year Ended
No.		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Segment Revenue						101.00
2	Healthcare	32.79	8.43	42.73	47.99	70.28	101.92
ian Ian	Rent on leasehold land	37.16	37.16	37.16	111.48	111.48	148.64
	Others	15.34	15.57	7.32	39.30	20.31	26.43
-	Total:	85.29	61.16	87.21	198.78	202.07	276.99
	Less: Inter Segment Revenue	2				and a	14 JANS
	Net Sales / Income from Operations	85.29	61.16	87.21	198.78	202.07	276.99
	Segment Results (Profit / Loss) before tax	M. TRAD	100		1	12-1-2-1	-
1	Healthcara	18.27	5.38	25.10	27.97	41.62	58.61
	Rent on leasehold land	36.93	36.93	36.93	110.79	110.79	148.64
	Others	15.34	15.57	7.32	39.30	20.31	26.43
	Total:	70.55	57.88	69.35	178.06	172.72	233.68
	Less:		1.4.4	1. 2. 1.	1000	- Hellow	- phane
	Interest		(4)		1	C. C. A.	1
	Other Unallocable Expenditure (net off)	41.10	29.14	44.38	103.92	100.74	
	Total Profit before Tax	29.45	28.74	24.97	74.14	71.98	96.69
3	Capital Employed				1	and a th	
1	(Segment Assets - Segment Liabilities)			12.0		The star	
a	Healthcare	23.04	11.47	1	100 C 200 m	10.22	the second se
b	Rent on leasehold land	(1.41)	(1.18)	(1.41)	(1,41)	(1.41)	
c	Others	713.46	505.31	628.52	713.46	628.52	
~	Total:	735.09	515.60	637.33	735.09	637.33	659.3

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature. The above results were taken on record at a meeting of the Board of Directors held on 3rd February, 2024.

Mumbai 3rd February 2024

For Emmessar Biotech & Nutrition Limited Srinivasa Raghavan Mathurakavi Ayyangar Chairman & Managing Director DIN: 00090266